Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.
Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.
Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.
For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.
Arcturus Therapeutics, a late-stage clinical mRNA medicines company, has appointed John Markels, Ph.D., to its Board of Directors. With over 35 years of industry experience, including as President of Global Vaccines at Merck, Dr. Markels will provide strategic oversight for the company's vaccine franchise and manufacturing processes. This appointment is expected to enhance Arcturus' efforts in developing novel self-amplifying mRNA vaccines in collaboration with CSL Seqirus, positioning the company for greater innovation in infectious disease vaccines.
Arcturus Therapeutics (Nasdaq: ARCT) announced a global partnership with CSL for developing self-amplifying mRNA vaccines, securing $200 million upfront and up to $4.3 billion in potential milestones. BARDA awarded $63.2 million for mRNA vaccine development targeting pandemic influenza. Recent data show the effectiveness of ARCT-032 in restoring chloride ion current in cystic fibrosis patients. For Q3 2022, Arcturus reported revenues of $13.4 million, a substantial increase from $2.4 million in Q3 2021, but a net loss of $35.3 million. Cash reserves stood at $237.7 million as of September 30, 2022.
Scholar Rock (NASDAQ: SRRK) appointed Dr. Jing L. Marantz as Chief Medical Officer, bringing over 20 years of experience in neurology, hematology/oncology, and rare diseases. Dr. Marantz, previously of Krystal Biotech, will oversee clinical development including the Phase 1 DRAGON trial for SRK-181 and Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy (SMA). CEO Jay Backstrom noted her expertise will enhance the company’s innovative approach to targeting TGFβ growth factors.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in two upcoming investor conferences. The Company will host a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 2:45 p.m. ET, and present at the 34th Annual Piper Sandler Healthcare Conference on November 29, 2022, at 11:30 a.m. ET. Arcturus focuses on developing mRNA medicines targeting infectious diseases and rare liver and respiratory conditions.
An agreement between Arcturus Therapeutics (NASDAQ: ARCT) and CSL Seqirus has been announced, positioning Arcturus for a potential financial boon. The collaboration includes an upfront payment of
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced it will release its financial results for Q3 2022 after market close on November 9, 2022. A conference call and webcast will follow at 4:30 PM EST. The company focuses on developing mRNA medicines for infectious diseases and rare liver and respiratory diseases. Arcturus' pipeline includes candidates for COVID-19, Influenza, and various genetic disorders. Founded in 2013 and based in San Diego, it employs innovative technologies like LUNAR® lipid-mediated delivery and STARR™ mRNA Technology.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced its participation in upcoming investor conferences. The company will attend the Jefferies Cell and Genetic Medicine Summit from September 29 to 30, 2022, and present at the Cantor Neurology & Psychiatry Conference on October 6, 2022, at 2:30 p.m. ET. Arcturus is focused on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases. To learn more, visit their website.
Arcturus Therapeutics (Nasdaq: ARCT) announced its participation in several upcoming investor conferences, highlighting its focus on mRNA medicines and vaccines. Key events include the Citi’s 17th Annual BioPharma Conference on September 6, 2022, and the Wells Fargo Virtual Healthcare Conference on September 9, 2022, among others. The company emphasizes its innovative technologies and diverse pipeline of therapies targeting infectious diseases and rare liver and respiratory conditions.
Arcturus Therapeutics has secured a
Arcturus Therapeutics (NASDAQ: ARCT) has released encouraging results from its ongoing ARCT-154 booster clinical trial, showing significant neutralizing antibody responses against Omicron variants for at least six months post-vaccination. Data revealed geometric mean fold rises (GMFR) of neutralizing antibodies: BA.1 (22-52), BA.2 (25-55), and BA.5 (9-24), indicating a strong immune response. The low-dose (5 mcg) booster showcased durability and breadth of response, highlighting Arcturus' innovative mRNA technology as a promising platform for infectious disease vaccines.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
